African Elephants Call Each Other by Unique Names, New Study Shows

 In this undated photo, an African elephant matriarch leads her calf away from danger in northern Kenya. (George Wittemyer via AP)
In this undated photo, an African elephant matriarch leads her calf away from danger in northern Kenya. (George Wittemyer via AP)
TT

African Elephants Call Each Other by Unique Names, New Study Shows

 In this undated photo, an African elephant matriarch leads her calf away from danger in northern Kenya. (George Wittemyer via AP)
In this undated photo, an African elephant matriarch leads her calf away from danger in northern Kenya. (George Wittemyer via AP)

African elephants call each other and respond to individual names — something that few wild animals do, according to new research published Monday.

The names are one part of elephants' low rumbles that they can hear over long distances across the savanna. Scientists believe that animals with complex social structures and family groups that separate and then reunite often may be more likely to use individual names.

“If you’re looking after a large family, you’ve got to be able to say, ‘Hey, Virginia, get over here!’” said Duke University ecologist Stuart Pimm, who was not involved in the study.

It’s extremely rare for wild animals to call each other by unique names. Humans have names, of course, and our dogs come when their names are called. Baby dolphins invent their own names, called signature whistles, and parrots may also use names.

Each of these naming species also possesses the ability to learn to pronounce unique new sounds throughout their lives — a rare talent that elephants also possess.

For the study in Nature Ecology & Evolution, biologists used machine learning to detect the use of names in a sound library of savanna elephant vocalizations recorded at Kenya's Samburu National Reserve and Amboseli National Park.

The researchers followed the elephants in jeeps to observe who called out and who appeared to respond — for example, if a mother called to a calf, or a matriarch called to a straggler who later rejoined the family group.

Analyzing only the audio data, the computer model predicted which elephant was being addressed 28% of the time, likely due to the inclusion of its name. When fed meaningless data, the model only accurately labeled 8% of calls.

“Just like humans, elephants use names, but probably don't use names in the majority of utterances, so we wouldn't expect 100%,” said study author and Cornell University biologist Mickey Pardo.

Elephant rumbles include sounds that are below the range of human hearing. The scientists still don't know which part of the vocalization is the name.

Researchers tested their results by playing recordings to individual elephants, who responded more energetically, ears flapping and trunk lifted, to recordings that contained their names. Sometimes elephants entirely ignored vocalizations addressed to others.

“Elephants are incredibly social, always talking and touching each other — this naming is probably one of the things that underpins their ability to communicate to individuals,” said co-author and Colorado State University ecologist George Wittemyer, who is also a scientific adviser for nonprofit Save the Elephants.

“We just cracked open the door a bit to the elephant mind.”



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”